Tag Archives: SCHOTT Pharma Maintains Stable Growth and Doubles Free Cash Flow in First Half of Fiscal 2026

SCHOTT Pharma Reports Solid H1 2026 Performance Driven by Strong Demand for Specialized Injectable Solutions

(IN BRIEF) SCHOTT Pharma delivered a resilient performance during the first half of fiscal year 2026, reporting revenue growth despite ongoing market challenges and maintaining strong profitability. The company benefited from continued demand for high-value pharmaceutical containment products, especially sterile … Read the full press release